Urinary Markers for Bladder Cancer Diagnosis and Monitoring

Jeong, Sangman; Ku, Ja Hyeon

doi:10.3389/fcell.2022.892067

Cited by 10 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An example is Prostate-Specific Antigen (PSA), which is a protein produced by the prostate gland, whose elevated urinary levels may indicate prostate cancer [ 79 ]. Other biomarkers that are being studied for their potential use in the detection and monitoring of cancer include Human Epididymis Protein 4 (HE4) for ovarian cancer [ 103 ], Bladder Tumor Antigen (BTA) for bladder cancer [ 104 ], and Matrix Metalloproteinases (MMPs) for various types of cancer, such as MMP-9 for breast cancer [ 105 ].…”

Section: Urine Proteins Biomarkersmentioning

confidence: 99%

Urinary Biomarkers and Point-of-Care Urinalysis Devices for Early Diagnosis and Management of Disease: A Review

Sequeira-Antunes

Ferreira

2023

Biomedicines

View full text Add to dashboard Cite

Biosensing and microfluidics technologies are transforming diagnostic medicine by accurately detecting biomolecules in biological samples. Urine is a promising biological fluid for diagnostics due to its noninvasive collection and wide range of diagnostic biomarkers. Point-of-care urinalysis, which integrates biosensing and microfluidics, has the potential to bring affordable and rapid diagnostics into the home to continuing monitoring, but challenges still remain. As such, this review aims to provide an overview of biomarkers that are or could be used to diagnose and monitor diseases, including cancer, cardiovascular diseases, kidney diseases, and neurodegenerative disorders, such as Alzheimer’s disease. Additionally, the different materials and techniques for the fabrication of microfluidic structures along with the biosensing technologies often used to detect and quantify biological molecules and organisms are reviewed. Ultimately, this review discusses the current state of point-of-care urinalysis devices and highlights the potential of these technologies to improve patient outcomes. Traditional point-of-care urinalysis devices require the manual collection of urine, which may be unpleasant, cumbersome, or prone to errors. To overcome this issue, the toilet itself can be used as an alternative specimen collection and urinalysis device. This review then presents several smart toilet systems and incorporated sanitary devices for this purpose.

show abstract

Section: Urine Proteins Biomarkersmentioning

confidence: 99%

Urinary Biomarkers and Point-of-Care Urinalysis Devices for Early Diagnosis and Management of Disease: A Review

Sequeira-Antunes

Ferreira

2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Commonly used methods for evaluating suspected BC patients include cystoscopy, urine cytology, ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) [32]. Cystoscopy, an invasive procedure, involves the insertion of a small tube into the bladder through the urethra to thoroughly examine and detect any potential abnormalities [33]. The sensitivity and specificity levels reported for cystoscopy range from 68 to 100% and 83 to 97%, respectively [33,34].…”

Section: Diagnosis and Prognosismentioning

confidence: 99%

Metabolomic Signatures of Treatment Response in Bladder Cancer

Vieira de Sousa,

Guedes de Pinho,

Pinto

2023

IJMS

View full text Add to dashboard Cite

Bladder cancer (BC) stands as one of the most prevalent urological malignancies, with over 500 thousand newly diagnosed cases annually. Treatment decisions in BC depend on factors like the risk of recurrence, the type of tumor, and the stage of the disease. While standard therapeutic approaches encompass transurethral resection of the bladder tumor, radical cystectomy, and chemo- or immunotherapy, these methods exhibit limited efficacy in mitigating the aggressive and recurrent nature of bladder tumors. To overcome this challenge, it is crucial to develop innovative methods for monitoring and predicting treatment responses among patients with BC. Metabolomics is gaining recognition as a promising approach for discovering biomarkers. It has the potential to reveal metabolic disruptions that precisely reflect how BC patients respond to particular treatments, providing a revolutionary method to improve accuracy in monitoring and predicting outcomes. In this article, we present a comprehensive review of studies employing metabolomics approaches to investigate the metabolic responses associated with different treatment modalities for BC. The review encompasses an exploration of various models, samples, and analytical techniques applied in this context. Special emphasis is placed on the reported changes in metabolite levels derived from these studies, highlighting their potential as biomarkers for personalized medicine in BC.

show abstract

“…The gold standard for clinical diagnosis is a costly invasive procedure that causes uncomfortable such as abdominal pain, and urgent and more frequent urination to patients [ 113 ]. To improve a patient’s quality of life and reduce the costs of cancer diagnosis, numerous researchers have been efforts to apply non-invasive diagnostic tests to find promising urinary cancer biomarkers such as cytokeratin-19, telomerase, and especially nuclear matrix protein-22 (NMP-22) [ 114 ]…”

Section: Detecting Other Biomolecules In Urine Samplementioning

confidence: 99%

Recent Advances in Biosensor Technologies for Point-of-Care Urinalysis

et al. 2022

View full text Add to dashboard Cite

Human urine samples are non-invasive, readily available, and contain several components that can provide useful indicators of the health status of patients. Hence, urine is a desirable and important template to aid in the diagnosis of common clinical conditions. Conventional methods such as dipstick tests, urine culture, and urine microscopy are commonly used for urinalysis. Among them, the dipstick test is undoubtedly the most popular owing to its ease of use, low cost, and quick response. Despite these advantages, the dipstick test has limitations in terms of sensitivity, selectivity, reusability, and quantitative evaluation of diseases. Various biosensor technologies give it the potential for being developed into point-of-care (POC) applications by overcoming these limitations of the dipstick test. Here, we present a review of the biosensor technologies available to identify urine-based biomarkers that are typically detected by the dipstick test and discuss the present limitations and challenges that future development for their translation into POC applications for urinalysis.

show abstract

Urinary Markers for Bladder Cancer Diagnosis and Monitoring

Cited by 10 publications

References 35 publications

Urinary Biomarkers and Point-of-Care Urinalysis Devices for Early Diagnosis and Management of Disease: A Review

Urinary Biomarkers and Point-of-Care Urinalysis Devices for Early Diagnosis and Management of Disease: A Review

Metabolomic Signatures of Treatment Response in Bladder Cancer

Recent Advances in Biosensor Technologies for Point-of-Care Urinalysis

Contact Info

Product

Resources

About